Background
==========

Hepatocellular carcinoma (HCC) is the fifth most frequently reported malignancy, with more than 500 000 new cases diagnosed each year \[[@b1-medscimonit-25-6615],[@b2-medscimonit-25-6615]\]. In the last decade, the incidence of HCC was approximately 0.4 per 1000 persons in the United States. HCC has become the third most common cause of cancer \[[@b3-medscimonit-25-6615]\]. Two-thirds of HCC patients are male, and the mean age of presentation is 63.7 years \[[@b4-medscimonit-25-6615]\]. China, Senegal, Gambia, and South Korea are high-incidence areas of HCC \[[@b2-medscimonit-25-6615]\]. HCC is most commonly associated with viral infection, including hepatitis B virus (HBV) (19.3%) and hepatitis C virus (HCV) (23.3%) infection. The second leading cause of HCC is nonalcoholic fatty liver disease (NAFLD), which accounts for approximately 24% of cases. In contrast, alcoholic steatohepatitis and cryptogenic hepatitis are less common causes of HCC, accounting for 12.7% and 15.3% of cases, respectively \[[@b5-medscimonit-25-6615]\]. Characteristics associated with metabolic syndrome, including obesity, type 2 diabetes mellitus (T2DM), hypertension, and hyperlipidemia, are also important pathogenic factors related to HCC \[[@b4-medscimonit-25-6615]\]. In addition, cirrhosis may be a critical risk factor for the development of liver cancer; however, research has shown that HCC can also occur in fatty liver disease, and this type of liver cancer is not associated with cirrhosis \[[@b6-medscimonit-25-6615]--[@b10-medscimonit-25-6615]\]. Notably, this type of HCC has not attracted enough attention and is often discovered at a late stage. In this study, we review the etiology, incidence, and clinical characteristics of HCC without cirrhosis, compare the treatment and prognosis of HCC in non-cirrhotic liver (HCC-NCL) and HCC in cirrhotic liver (HCC-CL), and discuss some screening markers and preventive measures to improve the knowledge and prevention of non-cirrhotic liver cancer.

Cause of HCC-NCL
================

HCC development may or may not go through the stage of cirrhosis. HCC-NCL is associated with chronic HBV or HCV infection, NAFLD/nonalcoholic steatohepatitis (NASH), dietary exposure to aflatoxins, hepatic adenoma, and fibrolamellar variations \[[@b11-medscimonit-25-6615]--[@b16-medscimonit-25-6615]\]. A small number of patients with HCC-NCL are infected with HBV. A study revealed that these patients are usually hepatitis B e antigen (HBeAg)-positive and have a low hepatitis B viral load \[[@b17-medscimonit-25-6615]\]. Some retrospective studies have shown that the most common cause of HCC-NCL is NAFLD \[[@b18-medscimonit-25-6615]--[@b20-medscimonit-25-6615]\]. In another study, 3 of 9 patients with HCC-NCL had NAFLD/NASH; the remaining patients had no potential chronic liver disease, but both groups of patients had more than 2 characteristics of metabolic syndrome \[[@b5-medscimonit-25-6615],[@b11-medscimonit-25-6615]\]. Some clinical studies and reviews also support the perspective that NAFLD/NASH and HCV infection primarily develop into HCC-NCL \[[@b21-medscimonit-25-6615]--[@b25-medscimonit-25-6615]\]. However, it takes a long time for only NASH and simple steatosis to develop into HCC \[[@b26-medscimonit-25-6615],[@b27-medscimonit-25-6615]\]. HCC-NCL induced by aflatoxins is more likely to be related to NAFLD/NASH \[[@b11-medscimonit-25-6615]--[@b15-medscimonit-25-6615]\]. In addition, a study investigating 193 patients with HCC found adeno-associated virus type 2 (AAV2) in 11 patients, which can lead to the development of HCC-NCL \[[@b28-medscimonit-25-6615]\]. Kyoung-Jin found that this viral fragment consists of 5′ inverted terminal repeat (ITR), replication protein (Rep), and capsid protein (VP1) in Korean patients \[[@b29-medscimonit-25-6615]\].

Incidence of HCC-NCL
====================

The incidence of HCC-NCL is differs across different countries and regions around the world \[[@b30-medscimonit-25-6615]\]. In European countries such as Italy, only 1.7% (52/3027) of HCC cases develop from non-cirrhotic liver disease. Based on a clinico-histopathological assessment of North American patients, 42.6% of 804 cases were HCC-NCL \[[@b31-medscimonit-25-6615]\]. Brancatelli \[[@b32-medscimonit-25-6615]\] also reported that 54% of 39 HCC patients in the United States had HCC-NCL. A systematic review of 19 randomized controlled trials concluded that 6.7% to 50.1% of HCC cases had no cirrhosis \[[@b26-medscimonit-25-6615]\]. Globally, the incidence of HCC caused by NAFLD is similar to that of HCC-NCL. A study in the United States showed that 27.6% (31/112) of patients with NAFLD-related HCC only had F0 to F2 stage disease (F0--F2 stages for non-cirrhotic disease and F3--F4 stages for cirrhotic disease). Another American study \[[@b10-medscimonit-25-6615]\] including 169 NAFLD patients from 25 small cohorts found that 40% of the patients had HCC-NCL. A study found non-cirrhotic liver in 40.2% (68/169) of patients with NAFLD-related HCC, and a retrospective study showed that 43% (36/83) of patients with NAFLD-related HCC had no evidence of cirrhosis \[[@b33-medscimonit-25-6615]\]. Furthermore, Japanese scholars have indicated that 38% of NAFLD-related HCC cases were non-cirrhotic \[[@b34-medscimonit-25-6615]\]. Finally, 2 studies from Germany showed lack of cirrhosis in 47.2% (17/36) and 22.2% (10/45) of NASH patients with liver cancer \[[@b5-medscimonit-25-6615],[@b35-medscimonit-25-6615]\].

Characteristics of HCC-NCL
==========================

Many studies have shown that the majority of patients with HCC-NCL are male. A German study with 93 patients with HCC-NCL reported a male-to-female ratio of 2.7: 1 \[[@b36-medscimonit-25-6615]\]. Typically, patients with HCC-NCL are older than patients with HCC-LC. A study in the United States found that patients with HCC-NCL had a mean age of 67.5 years old, while patients with HCC-LC had a mean age of 62.7 years old. A German study showed similar results, with mean ages of 69 and 66 years, respectively \[[@b33-medscimonit-25-6615],[@b36-medscimonit-25-6615]\]. The median age of male patients is 71 years, and that of female patients is 66 years \[[@b36-medscimonit-25-6615]\]. An Australian study showed that the average age of NAFLD patients with HCC-LC was 69 years and that NAFLD patients with NCL-HCC were generally older \[[@b35-medscimonit-25-6615]\]. Moreover, scholars in France found that a lower degree of fibrosis in the paracancerous tissues of HCC was associated with a larger tumor diameter (F0--F2 stage tumors were 10.1±6.7 cm and F3--F4 stage tumors were 6.6±3.5 cm in diameter) \[[@b9-medscimonit-25-6615]\]. We examined several cases without obvious fibrosis and found that the median size of HCC lesions was 5.33±4.58 cm \[[@b6-medscimonit-25-6615],[@b11-medscimonit-25-6615],[@b23-medscimonit-25-6615],[@b37-medscimonit-25-6615]--[@b45-medscimonit-25-6615]\]. HCC-NCL tumors are also more likely to be highly differentiated. Studies have found that 75% (15/20) of highly differentiated tumors are in F0--F2 stage, while only 45% (5/11) of highly differentiated tumors are in F3--F4 stage \[[@b9-medscimonit-25-6615],[@b35-medscimonit-25-6615]\]. Another clinicopathological study came to a similar conclusion, showing that in HCC-NCL, 83% (5/6) of the tumors had moderate differentiation and 16% (1/6) had high differentiation, with a small number of tumors with low differentiation \[[@b23-medscimonit-25-6615]\]. Furthermore, HCC lesions can be single or multiple. HCC-NCL more often presents as single tumors than does HCC-CL \[[@b46-medscimonit-25-6615]\]. One study including 31 cases of HCC without significant fibrosis showed that in 23 of the cases, the lesion was surrounded by an envelope, while 8 were lacked an envelope. In contrast, all examined HCC-CL lesions were enveloped. Additionally, in contrast with HCC-CL, HCC-NCL has satellite nodules and vascular invasion, but the difference is not statistically significant \[[@b9-medscimonit-25-6615]\]. The incidence of portal vein thrombosis is almost equal in HCC patients with and without cirrhosis. Patients with HCC-NCL display no clinical symptoms at the early stage and can have asymptomatic masses, and their liver function, especially in the case of NASH patients with HCC, is not significantly abnormal \[[@b17-medscimonit-25-6615],[@b23-medscimonit-25-6615],[@b47-medscimonit-25-6615],[@b48-medscimonit-25-6615]\]. Furthermore, compared with HCC-CL, HCC-NCL is usually accompanied by normal alpha-fetoprotein (AFP) levels \[[@b48-medscimonit-25-6615]\].

Therefore, although HCC-NCL is often discovered during physical examination, unfortunately, it is usually found at a late stage. Lobular inflammation occurs in 63.6% of patients with HCC-NCL. Additionally, patients with HCC-NCL have relatively fewer Mallory bodies in biopsy specimens \[[@b33-medscimonit-25-6615]\]. Furthermore, for young women on oral contraceptives, hepatocellular adenoma (HCA) has a higher risk of progressing to HCC \[[@b49-medscimonit-25-6615]\], but HCC evolving from HCA can occur without significant fibrosis \[[@b9-medscimonit-25-6615]\].

Relationship between HCC-NCL and Metabolic Disorders
====================================================

HCC-NCL is closely related to metabolic disorders. Some studies have found that HCC patients with metabolic disorders do not have significant fibrosis (65.5% \[20/31\] of cases have F0--F2 disease) \[[@b9-medscimonit-25-6615]\]. Some clinical researchers have found that most patients with HCC-NCL are diagnosed with metabolic disorders. Approximately 33.3% of patients with HCC-NCL have a body mass index (BMI) of more than 25 kg/m^2^, 45.16% are diagnosed with diabetes, and 40% (22/55) have a history of nicotine abuse \[[@b36-medscimonit-25-6615]\].

The main cause of HCC-NCL is NAFLD/NASH, and NASH is closely related to metabolic disorders. Metabolic disorders are also closely related to HCC. One study showed that 98.6% (71/72) of patients with NAFLD-related HCC had at least 1 type of metabolic disorder, and 76.4% (55/72) had 2 or more types \[[@b5-medscimonit-25-6615]\].

Independent risk factors for HCC associated with NASH include obesity (BMI \>25 kg/m^2^, present in approximately 95% of NASH patients), T2DM (in approximately 64% of NASH patients compared with other liver diseases), hypertension (in more than 70% of NASH patients), hyperlipidemia (in approximately 50% of NASH patients), coronary artery disease (in approximately 30.6% of NASH patients), and heart failure (in approximately 17.5% of NASH patients) \[[@b5-medscimonit-25-6615],[@b11-medscimonit-25-6615],[@b23-medscimonit-25-6615],[@b50-medscimonit-25-6615]\].

Treatment of HCC-NCL
====================

Treatments for HCC include oral or intravenous chemotherapy, surgery, liver transplantation, transarterial chemoembolization (TACE), radiofrequency ablation (RFA), alcohol ablation, preoperative portal vein embolization, and sorafenib therapy (multitarget tyrosine kinase inhibitors extend the survival of HCC patients who cannot undergo resection or transplantation) \[[@b4-medscimonit-25-6615],[@b51-medscimonit-25-6615],[@b52-medscimonit-25-6615]\]. In the absence of obvious fibrosis, the main treatment methods for HCC are hepatectomy, liver transplantation, and local ablation \[[@b36-medscimonit-25-6615],[@b53-medscimonit-25-6615],[@b54-medscimonit-25-6615]\]. The indications for surgery are isolated tumors without liver cirrhosis or portal hypertension. Since the livers of patients with HCC-NCL are healthier than those of HCC-CL patients, hepatectomy is more feasible in patients with HCC-NCL \[[@b48-medscimonit-25-6615],[@b55-medscimonit-25-6615]--[@b57-medscimonit-25-6615]\]. The proportions of patients with HCC-NCL and HCC-CL receiving hepatectomy, palliative treatment, TACE/RFA, and liver transplantation are 66.7%, 13.9%, 22.3% and 0% and 17%, 0%, 61.7%, and 72.3%, respectively \[[@b33-medscimonit-25-6615],[@b44-medscimonit-25-6615]\]. Some studies claim that patients with HCC-NCL are not good candidates for liver transplantation \[[@b35-medscimonit-25-6615],[@b48-medscimonit-25-6615],[@b58-medscimonit-25-6615],[@b59-medscimonit-25-6615]\]. In 2 recent studies from the United States, no patients with HCC-NCL underwent liver transplantation \[[@b11-medscimonit-25-6615],[@b33-medscimonit-25-6615]\]. HCV infection is also an important cause of HCC-NCL. Notably, HCV-infected patients with NAFLD-related HCC are more likely to undergo transplantation than patients with NAFLD/NASH alone \[[@b4-medscimonit-25-6615]\].

Prognosis of HCC-NCL
====================

The mortality rate of patients with HCC-NCL is similar to that of patients with HCC-CL, even though HCC-CL can be found early, while HCC-NCL is usually found at a late stage. Late diagnosis is an important reason for the poor prognosis of patients with HCC-NCL. A study in the United States showed that the 1-year disease-free survival rate of patients with HCC-NCL was 63%, and the 3-year and 5-year survival rates were 39% and 31%, respectively \[[@b60-medscimonit-25-6615]\]. Another American study showed similar results: the 1-year and 5-year overall survival rates of patients with HCC-NCL were 84.6%, and 38.4%, respectively \[[@b51-medscimonit-25-6615]\]. Additionally, in Italy, the median overall survival time was 26 months, and the 5-year survival rate was 23.7%, close to that in the United States \[[@b61-medscimonit-25-6615]\], but the 5-year survival rates were not significantly different. There was no significant difference in 5-year survival between patients with HCC-NCL and those with HCC-CL \[[@b33-medscimonit-25-6615]\]. A recent cohort study confirmed that the median survival rates of patients with HCC-NCL diagnosed with Barcelona Clinic Liver Cancer (BCLC) stage A, B, and C disease were 945, 925, and 229 days, respectively \[[@b36-medscimonit-25-6615]\].

Older age is closely related to increased mortality of all patients with HCC-NCL. Mortality can increase by 10% with each year increase in age \[[@b33-medscimonit-25-6615]\]. Patients with HCC-NCL also have a high recurrence rate (86% in the United States and 39% in the Netherlands) \[[@b33-medscimonit-25-6615],[@b44-medscimonit-25-6615]\], especially intrahepatic recurrence \[[@b48-medscimonit-25-6615]\]. According to TNM stages, the cumulative probability of stratified recurrence is 33.7% at 1 year and 57.5% at 5 years\[[@b51-medscimonit-25-6615]\]. Additionally, patients with HCC-NCL who are infected with HBV have a longer survival time than patients with HCC-CL (21 *vs.* 11 months) \[[@b17-medscimonit-25-6615]\]. Furthermore, patients with HCC-NCL undergoing hepatectomy have a significantly better prognosis than patients receiving nonsurgical treatment \[[@b60-medscimonit-25-6615]\]. After curative hepatectomy, no significant difference is observed in the survival rate between patients with HCC-NCL with and without HBV infection. The overall survival rates of patients with HCC-NCL with and without NASH were 43.4 months and 25 months, respectively, but without a significant difference \[[@b62-medscimonit-25-6615]\].

Researchers have identified various prognostic factors influencing the recurrence and overall survival of patients with HCC-NCL, including perioperative blood transfusion, portal vein thrombosis, vascular invasion, lymph node positivity, tumor size, nodular state, presence of satellite nodule, marginal state, and tumor grade \[[@b63-medscimonit-25-6615]--[@b69-medscimonit-25-6615]\] Recent retrospective studies have shown that increased preoperative gamma glutamyl transferase (GGT) and AFP levels may be a new adverse prognostic factor for primary HCC-NCL \[[@b70-medscimonit-25-6615],[@b71-medscimonit-25-6615]\]. Patients with the best prognosis had small HCC lesions without vascular invasion or satellite nodules and had undergone R0 resection without intraoperative blood transfusion\[[@b48-medscimonit-25-6615]\]. We summarize the incidence, age, tumor size and status, treatment, recurrence, and mortality of HCC-NCL in the [Table 1](#t1-medscimonit-25-6615){ref-type="table"}.

Prevention of HCC-NCL
=====================

HCC has no special manifestations in the early stage. Similar to other tumors, it is usually diagnosed when symptoms begin to emerge. NAFLD is a common cause of HCC-NCL, and NAFLD is easily overlooked because it is considered a benign condition. With improvements in living standards and changes in dietary habits, T2DM, obesity, NAFLD, and metabolic disorders are becoming increasingly common worldwide. NAFLD is becoming more common in developing countries, and it affects more than 30% of the population in industrialized countries \[[@b11-medscimonit-25-6615],[@b72-medscimonit-25-6615],[@b73-medscimonit-25-6615]\]. Due to increased incidence of NAFLD, the incidence of NAFLD-related HCC has also increased annually in recent years. Therefore, early detection of NAFLD is important for the prevention of HCC-NCL.

Generally, doctors only screen or monitor patients with cirrhosis for preventing HCC \[[@b11-medscimonit-25-6615]\]. HCC-NCL developed in NAFLD is easily overlooked in clinical practice, and there are no screening guidelines for it. Therefore, the disease becomes severe before diagnosis, resulting in a poor prognosis \[[@b33-medscimonit-25-6615],[@b74-medscimonit-25-6615]\].

Currently, we lack screening guidelines for NAFLD-related HCC-NCL, which could otherwise reduce the severe morbidity. Moreover, healthcare providers may not realize the importance of screening for HCC-NCL \[[@b4-medscimonit-25-6615]\]. According to the 2012 American Association for the Study of Liver Diseases (AASLD) guidelines, "the risk of NAFLD-HCC may be limited to patients with advanced fibrosis and cirrhosis" \[[@b75-medscimonit-25-6615]\], but there are no specific recommendations for diagnosis and treatment.

The European Association for the Study of the Liver (EASL) states that it is impractical to systematically monitor and screen for the presence of HCC risk in patients with NAFLD and to stratify the risk of liver cancer in the NAFLD population through the study of genetic polymorphisms, as it is costly \[[@b76-medscimonit-25-6615]\]. In addition, abdominal ultrasound monitoring is less likely to detect tumors when screening patients with NAFLD, due to attenuations of ultrasound beams; the liver appears bright on ultrasound images, with uneven echo features and focal fat infiltration, leading to a low recognition rate or high misreading rate for small nodules \[[@b77-medscimonit-25-6615],[@b78-medscimonit-25-6615]\]. Thus far, there is still no clear guidance on how to prevent HCC through intervention of NAFLD.

Mechanisms and Markers of HCC-NCL
=================================

Only a handful of studies on the mechanism of HCC-NCL exist, and the available studies mainly involve basic research on NAFLD/NASH-related HCC. For example, hepatic 8-hydroxy-2′-deoxyguanosine (8-OHdG) content may serve as a marker of oxidative stress and could be a particularly useful predictor of NASH-related HCC \[[@b79-medscimonit-25-6615]\]. In human NAFLD-related HCC, squalene epoxidase (SQLE) is overexpressed, and its expression is associated with poor patient outcomes \[[@b80-medscimonit-25-6615]\]. Activation of apoptosis inhibitor of macrophage (AIM), which usually is associated with IgM pentamers in blood, is a sensitive diagnostic marker for NASH-related HCC \[[@b81-medscimonit-25-6615]\]. Mutations in the telomerase reverse transcriptase (TERT) promoter and chromosome 8p loss are characteristics of NAFLD-related HCC \[[@b82-medscimonit-25-6615]\]. Apoptosis antagonizing transcription factor (AATF) also offers a potential target for therapeutic intervention of NAFLD-related HCC \[[@b83-medscimonit-25-6615]\]. Furthermore, the PNPLA3 rs738409 C\>G polymorphism is associated with a high risk of advanced NAFLD-related HCC \[[@b84-medscimonit-25-6615]\]. Caveolin (CAV)-1 is also overexpressed in clinical specimens from patients with NAFLD-related HCC and is a potential therapeutic target in these patients \[[@b85-medscimonit-25-6615]\]. MicroRNA (miR)-21 plays a causative role in NAFLD and HCC via modulation of the HBP1-p53-Srebp1c pathway *in vivo* and *in vitro* \[[@b86-medscimonit-25-6615]\]. Histone deacetylase (HDAC)-8 promotes insulin resistance and β-catenin activation in NAFLD-related HCC and offers a novel epigenetic target to prevent or treat HCC in obese patients \[[@b87-medscimonit-25-6615]\]. p62 potentially represents a critical pathophysiological factor in NAFLD-related HCC \[[@b88-medscimonit-25-6615]\]. Cisd2 interacts with Serca2b to regulate Ca2+ homeostasis in hepatocytes, and Cisd2 haploinsufficiency induces NAFLD/NASH and promotes HCC development \[[@b89-medscimonit-25-6615]\].

Nevertheless, it is crucial to find a specific marker to detect HCC-NCL in patients. Certain noninvasive tests and biomarkers may help screen and monitor HCC-NCL. For example, immunohistochemical markers such as CD34, cytokeratin (CK)-7, CK19, phosphatidylinositol proteoglycan 3 (GPC-3), glutamine synthase, and β-catenin may help in the diagnosis and prediction of HCC-NCL \[[@b90-medscimonit-25-6615]--[@b92-medscimonit-25-6615]\]. In recent years, some studies have found that the level of activity regulator of SIRT1 (AROS) is significantly correlated with tumor size, tumor diversity, vascular invasion, and tumor differentiation, as well as disease-free survival rate, and can be used as a marker for the detection of HCC-NCL \[[@b93-medscimonit-25-6615]\]. MiRs are 18--25 nucleotide noncoding RNAs that can regulate gene expression \[[@b94-medscimonit-25-6615]\]. For example, the levels of miR-24 and miR-27a in HCC-CL are significantly reduced, while miR-21 levels are generally increased in HCC-NCL \[[@b95-medscimonit-25-6615]\]. A Chinese study noted that increased hsa-miR-1296 and hsa-miR-149 expression, as well as TNM stages, were risk factors of HCC-NCL, whereas increased hsa-miR-23c expression was associated with improved survival in patients with HCC-NCL. High expression of hsa-mir-149 was found to be an independent risk factor for prognosis in HCC-NCL \[[@b94-medscimonit-25-6615]\]. Relative telomere length (RTL) in circulating cell-free serum DNA is significantly correlated with HCC risk and may be a new noninvasive biomarker of HCC-NCL in the presence of HBV infection \[[@b96-medscimonit-25-6615]\]. Italian researchers have found that the T allele of membrane-bound O-acyl transferase (MBOAT)-7 at rs641738 can reduce the expression of MBOAT 7, resulting in an increased prevalence of HCC-NCL. These authors used this noninvasive biomarker to detect NAFLD-related HCC-NCL \[[@b97-medscimonit-25-6615]\]. Furthermore, contrast-enhanced magnetic resonance imaging (MRI) monitoring is also applicable for patients with vascular liver disease associated with HCC-NCL \[[@b98-medscimonit-25-6615],[@b99-medscimonit-25-6615]\].

Conclusions
===========

The number of patients with NAFLD has dramatically increased, and the prevalence of NAFLD-related HCC has also increased. HCC-NCL is becoming a major public health challenge due to the lack of specific monitoring tools, which limits the possibility of treatment due to delayed diagnosis. At present, there is no relevant guideline for its diagnosis and treatment. Thus, for the general population, the best and only possible effective strategy is prevention. Therefore, public awareness of this disease should be advocated to achieve effective prevention.
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Epidemiology and characteristics of NAFLD/NASH-HCC.

  Year   Authors               PMID       Country     Statistics time (years)   Patient source                                                                                    Race                                                                                    Total people   Male              NAFLD/ NASH-HCC ratio   NAFLD/NASH-HCC-NCL ratio
  ------ --------------------- ---------- ----------- ------------------------- ------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- -------------- ----------------- ----------------------- --------------------------
  2008   Grace G et al.        18976012   USA         2004--2007                The University of Illinois at Chicago Medical Center                                              N                                                                                       50             66.7% (2/3)       N                       6% (3/50)
  2009   Chagas AL et al.      19787150   Brasil      1998--2006                Department of Gastroenterology of Clinic Hospital of University of São Paulo School of Medicine   N                                                                                       394            57% (4/7)         1.7% (7/394)            14.2% (1/7)
  2009   Paradis V et al.      19115377   France      1995--2007                Beaujon Hospital                                                                                  N                                                                                       128            96% (30/31)       24% (31/128)            35% (11/31)
  2009   Kawada N et al.       19672551   Japan       1990--2006                Osaka Medical Center for Cancer and Cardiovascular Diseases                                       N                                                                                       807            50% (3/6)         1% (8/807)              75% (6/8)
  2011   Ertle J et al.        21128245   Germany     2007--2008                Department of Gastroenterology and Hepatology at University Hospital Essen                        Central Europe: 125, Southern Europe: 14, Eastern Europe: 4, Asia: 7                    162            83.3% (125/162)   24% (36/162)            11% (4/36)
  2012   Duan XY et al.        22251466   China       1990--2010                Pubmed database                                                                                   Australia: 1, Brazil: 1, Japan: 80, France: 23, UK: 2, Spain: 2, USA: 24, Germany: 36   169            72.8% (123/169)   100% (169/169)          40% (68/169)
  2013   Alexander J et al.    23302015   USA         1990--2010                Three tertiary care centers in the United States                                                  N                                                                                       157            64% (101/157)     15.3% (24/157)          N
  2014   Schütte K et al.      24990270   Germany     1994--2013                The University Hospital of Magdeburg                                                              N                                                                                       664            73% (68/93)       N                       14% (93/664)
  2015   Perumpail RB et al.   26250831   USA         2010--2012                Brooke Army Medical Center (BAMC)                                                                 N                                                                                       44             83.3% (5/6)       N                       13.6% (6/44)
  2015   Mohamad B et al.      26558795   USA         2003--2012                Cleveland Clinic Foundation                                                                       White: 77,African American: 4,other: 2                                                  83             65% (54/83)       N                       43% (36/83)
  2015   Leung C et al.        25632192   Australia   2000--2012                The Victorian Liver Transplant Unit                                                               N                                                                                       54             87% (47/54)       13% (39/54)             20.5% (8/39)
  2015   Weinmann A et al.     25884354   Germany     2000--2010                University Medical Centre of the JohannesGutenberg University Mainz                               Caucasian origin: 1100 (98.3%)                                                          1119           77.8% (35/45)     4.0% (45/1119)          N
  2015   Younossi ZM et al.    26274335   USA         2004--2009                Surveillance, Epidemiology and End Results (SEER)-Medicare linked database                        White: 3031 (60.9%) Other: 1348 (39.1%)                                                 4 979          61.3% (430/401)   14.1% (701/4979)        N

  Year   HCC-NCL tumor diameter (cm)   HCC-NCL tumor status     HCC-NCL age (years)   HCC-NCL influencing factor                                                                                                                HCC-NCL treatment                                                                                                                                                                                                                             Mortality rate   Recurrence rate   Reference
  ------ ----------------------------- ------------------------ --------------------- ----------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------- ----------------- ----------------------------
  2008   0.5--10                       N                        57±13                 Obesity, diabetes, hypertension, dyslipidemia                                                                                             N                                                                                                                                                                                                                                             N                N                 [@b77-medscimonit-25-6615]
  2009   1.0--5.2                      A single nodule: 57%     63±13                 Obesity, hypertension, dyslipidemia, hyperuricemia                                                                                        N                                                                                                                                                                                                                                             N                N                 [@b6-medscimonit-25-6615]
  2009   N                             A single nodule: 78%     67±7                  Obesity, diabetes, hypertension, dyslipidemia                                                                                             N                                                                                                                                                                                                                                             N                N                 [@b9-medscimonit-25-6615]
  2009   N                             N                        N                     Obesity, diabetes, hypertension, dyslipidemia                                                                                             Hepatic resection: 100%                                                                                                                                                                                                                       N                N                 [@b23-medscimonit-25-6615]
  2011   N                             N                        68.6±8.4              Obesity, diabetes, hypertension, dyslipidemia                                                                                             N                                                                                                                                                                                                                                             N                N                 [@b5-medscimonit-25-6615]
  2012   0.8--20                       A single nodule: 76%     67                    Obesity, diabetes, hypertension, dyslipidemia                                                                                             Tumor resection: 57.7%, liver transplantation: 14.6%, percutaneous ethanol injection: 3.1%, radiofrequency ablation: 8.5%, transarterial embolization: 19.2%, transarterial infusion chemotherapy: 1.5%,microwave coagulation therapy: 0.8%   32,40%           18,80%            [@b10-medscimonit-25-6615]
  2013   N                             N                        63.8±12.5             Diabetes, hypertension, dyslipidemia                                                                                                      Hepatic resection: 100%                                                                                                                                                                                                                       N                N                 [@b90-medscimonit-25-6615]
  2014   N                             N                        69 (32--85)           Obesity, hypertension                                                                                                                     Resection: 23.66%,RFA/thermoablation: 5.38%, liver transplantation: 1.08%                                                                                                                                                                     N                N                 [@b35-medscimonit-25-6615]
  2015   N                             N                        72±8                  Obesity, diabetes, hypertension, dyslipidemia                                                                                             Right hepatectomies: 33%, core liver biopsies: 50%                                                                                                                                                                                            N                N                 [@b11-medscimonit-25-6615]
  2015   N                             A single nodule: 80.6%   67.5±12.3             Obesity, positive family history of cancer, diabetes, metabolic syndrome, hypertension, smoking, alcohol consumption                      Hepatic resection: 66.7%, loco-regional therapy: 22.3%                                                                                                                                                                                        47%              86%               [@b32-medscimonit-25-6615]
  2015   4,7                           N                        65                    Obesity, diabetes, hypertension, dyslipidaemia                                                                                            Liver transplantation: 12.5%                                                                                                                                                                                                                  N                N                 [@b34-medscimonit-25-6615]
  2015   1.5--16.5                     N                        67.6                  Obesity, diabetes, hypertension, cardiovascular complications, dyslipidemia, myocardial infarction, apoplectic stroke, thrombocytopenia   Resection or orthotopic liver transplantation: 4.4%                                                                                                                                                                                           N                N                 [@b46-medscimonit-25-6615]
  2015   N                             N                        73±8                  Male, race, any type of chronic liver diseases                                                                                            Liver transplantion: 5.7%                                                                                                                                                                                                                     61.20%           N                 [@b84-medscimonit-25-6615]

N -- not repotred.
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